Overview

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The study is aimed at evaluating the safety of L19TNF in combination with the most appropriate dose of doxorubicin.
Phase:
Phase 1
Details
Lead Sponsor:
Philogen S.p.A.
Treatments:
Doxorubicin
Liposomal doxorubicin